Patients with pulmonary arterial hypertension (PAH) who were treated with treprostinil using an implantable infusion pump experienced few serious complications.
Predicting bleeding during cardiopulmonary bypass is complex and not captured by tests, including measuring von Willebrand factor interaction.
A combinatorial model was devised to predict pulmonary hypertension using systolic pulmonary artery pressure and forced vital capacity in older adults.
Pulmonary artery denervation has been found to reduce the sympathetic activity of the pulmonary circulation.
Elevated pulmonary artery systolic pressure was found to be associated with a worse prognosis in patients with heart failure with severe secondary mitral regurgitation.
A new dissociated pulmonary vein activity was detected in a patient.
Researchers sought to determine if selexipag can be associated with lower hospitalization rates through analysis of real-world hospitalization rates of patients taking either selexipag or treprostinil.
Physicians frequently underestimate or overestimate disease progression risk in patients with World Health Organization functional class II pulmonary arterial hypertension.
Diagnosing pulmonary hypertension due to left-heart disease requires a systematic approach using clinical history and noninvasive investigations.
The purpose of this study was to determine whether baseline pulmonary hypertension influences the outcome of transcatheter mitral valve repair (TMVr) in patients presenting with HF with SMR.
